APHIOS
CORPORATION ANNOUNCES LAUNCH OF
SUPERCOOL ST. JOHN FOR EMOTIONAL WELL-BEING,
RELAXED OUTLOOK AND POSITIVE MOOD
July
13, 2004 - Aphios
Corporation today announced its launch of SuperCool™
St. John for mild to moderate mood swings and feelings of
well-being.
SuperCool™
St. John is an advanced formulation of an enhanced hyperforin
fraction of the flowers, buds and stems of St. John’s
Wort (Hypericum perforatum, SJW), a bushy perenial that
blooms around St. John the Baptist day (June 24). Aphios’
SuperCool™
St. John product is standardized against hyperforins that
show a linear dose response with serotonin reuptake inhibition
[U.S. Patent No. 6,291,241B1, Castor et al., 2001]. Aphios’
scientists and collaborators have shown that hyperforins
are effective serotonin reuptake inhibitors (SRIs).
SuperCool™
St. John was discovered and is manufactured utilizing patented
SuperFluids™
carbon dioxide technologies that are nontoxic and environment
friendly. The product is formulated and encapsulated by
Capsugel, Inc., a subsidary of Pfizer, Inc. in accordance
with cGMP (current Good Manufacturing Practices) of the
United States Food and Drug Administration (FDA).
SuperCool™
St. John also contains natural Vitamin E and natural mixed
tocopherols in Extra Virgin olive oil. This advanced superantioxidant
formulation is designed to protect the active ingredients,
hyperforins, while providing the consumers with an additional
nutritional (antioxidant) benefit. This advanced formulation
[U.S. Patent Pending, 2004] also includes lecithin, an emulsifier,
to increase the bioavailability of the poorly water-soluble
but highly permeable hyperforins. SuperCool™
St. John is encapsulated in L-Vcaps™,
liquid vegetable capsules, and does not contain any animal
byproducts.
SuperCool™
St. John has not been evaluated by the FDA and is not intended
to diagnose, treat, cure or prevent disease. As with any
dietary supplement, consumers should consult their physican
before taking this product and should be aware of contraindications
when taking prescription medicines such as protease inhibitors,
cyclosporine, birth control pills and antidepressants. Research
leading to the development of SuperCool™
St. John was funded, in part, by the National Center for
Complimentary Medicine (NCCAM), National Institutes of Health
(NIH).
Aphios
Corporation (www.aphios.com)
is a biopharmaceutical company that is developing enhanced
natural therapeutics for health maintenance and the treatment
of human diseases with a focus on infectious diseases, oncology
and CNS disorders. For more information on SuperCool™
St. John, please visit www.supercoolhealth.com.
###
